Parihar AS, Mittal BR, Sood A et al (2020b) ⁶⁸Ga-PSMA-HBED-CC PET/CT and ¹⁸F-FDG

PET/CT in Ewing sarcoma. Clin Nucl Med 45(1):e57–e58

Parihar AS, Sood A, Sood A et al (2020c) Demonstration of focal physiologic in-vivo somatostatin

receptor expression in the caput epididymis of the testes on ⁶⁸Ga-DOTANOC PET/CT and

177Lu-DOTATATE post-therapy whole body scintigraphy. Asia Ocean J Nucl Med Biol 8(2):

132–135

Parihar AS, Chandekar K, Singh H et al (2021) Orbital and brain metastases on 68Ga-PSMA

PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA

therapy. Asia Ocean J Nucl Med Biol 9(1):67–70

Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic

prostate cancer. N Engl J Med 369:213–223

Prasad V, Baum RP (2010) Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-

NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and

tumor lesions. QJ Nucl Med Mol Imaging 54(1):61–67

Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP (2010) Detection of unknown

primary neuroendocrine tumours (CUP-NET) using 68 Ga-DOTA-NOC receptor PET/CT. Eur

J Nucl Med Mol Imaging 37(1):67

Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W (2016a) Biodistribution of

[68 Ga] PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal

organs and tumour lesions. Mol Imaging Biol 18(3):428–436

Prasad V, Sainz-Esteban A, Arsenic R, Plöckinger U, Denecke T, Pape UF, Pascher A, Kühnen P,

Pavel M, Blankenstein O (2016b) Role of 68 Ga somatostatin receptor PET/CT in the detection

of endogenous hyperinsulinaemic focus: an explorative study. Eur J Nucl Med Mol Imaging

43(9):1593–1600

Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, Montironi R

(2014) Targeting prostate-specific membrane antigen for personalized therapies in prostate

cancer: morphologic and molecular backgrounds and future promises. J Biol Regul Homeost

Agents 28(4):555–563

Satapathy S, Das CK, Parihar AS, Sood A, Mittal BR (2021) Response to concomitant

enzalutamide and 177Lu-PSMA-617 radioligand therapy in ATM-mutated metastatic castration

resistant prostate cancer. Clin Nucl Med. https://doi.org/10.1097/RLU.0000000000003541

Sathekge M, Bruchertseifer F, Knoesen O et al (2019) 225Ac-PSMA-617 in chemotherapy-naive

patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging 46:129–138

Schmidt M, Simon T, Hero B, Schicha H, Berthold F (2008) The prognostic impact of functional

imaging with 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk

treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 44(11):

1552–1558

Seidlin SM, Rossman I, Oshry E, Siegel E (1949) Radioiodine therapy of metastases from

carcinoma of the thyroid: a six-year progress report. J Clin Endocrinol 9(11):1122–1137

Sharma S, Singh B, Mishra AK, Rathod D, Hazari PP, Chuttani K, Chopra S, Singh PM, Abrar ML,

Mittal BR, Singh G (2014) Lat-1 based primary breast cancer detection by [99m] tc-labeled

dtpa-bis-methionine scintimammography: first results using indigenously developed single vial

kit preparation. Cancer Biother Radiopharm 29(7):283–288

Singh B, Prasad V, Schuchardt C, Kulkarni H, Baum RP (2013) Can the standardized uptake values

derived from diagnostic 68Ga-DOTATATEPET/CT imaging predict the radiation dose deliv-

ered to the metastatic liver NET lesions on 177Lu-DOTATATE peptide receptor radionuclide

therapy. J Postgrad Med Educ Res 47:7–13

Singh B, Sharma S, Bansal P, Hooda M, Singh H, Parihar AS, Kumar A, Watts A, Mohan R, Singh

SK (2021) Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-

PSMA-11 PET/CT in the detection of metastatic prostate cancer and dosimetry analysis: a

gamma-camera-based alternate prostate-specific membrane antigen imaging modality. Nucl

Med Commun 42(5):482–489

7

Precision Radiomolecular Oncology: Challenging the Classical Statistical. . .

109